Tyra Biosciences, Inc.
TYRA- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001863127
In the last 90 days, Tyra Biosciences, Inc. insiders filed 1 open-market purchase and 0 sales; 168 institutions reported holding it in 13F filings for Q2 2026, worth $2.22B in total; no superinvestor holds it.
13F holders, Q4 2024
Institutional positions in Tyra Biosciences, Inc. as of Dec 31, 2024. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 113
- +18 vs. Q3 2024
- Shares held
- 48.6M
- +1.56M (+3.3%) vs. Q3 2024
- Total value
- $675.8M
- −$430.2M (−38.9%) vs. Q3 2024
- New holders
- 36
- 34 more added
- Sold out
- 18
- 25 more reduced
Compare with Q3 2024: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting TYRA on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 168 | $2.22B |
| Q1 2026 | 164 | $2.52B |
| Q4 2025 | 133 | $1.49B |
| Q3 2025 | 116 | $778.4M |
| Q2 2025 | 121 | $541.5M |
| Q1 2025 | 117 | $499.5M |
| Q4 2024 | 113 | $675.8M |
| Q3 2024 | 95 | $1.11B |
| Q2 2024 | 79 | $748.6M |
| Q1 2024 | 77 | $768.4M |
| Q4 2023 | 62 | $495.2M |
| Q3 2023 | 59 | $502.1M |
| Q2 2023 | 59 | $616.7M |
| Q1 2023 | 51 | $573.0M |
| Q4 2022 | 46 | $267.8M |
| Q3 2022 | 49 | $313.8M |
| Q2 2022 | 48 | $255.6M |
| Q1 2022 | 46 | $386.6M |
| Q4 2021 | 45 | $494.2M |
| Q3 2021 | 26 | $456.8M |
| Q2 2021 | 0 | $0 |
| Q1 2021 | 0 | $0 |
Institutions, Q4 2024
Shares, value and share of portfolio for each institution holding Tyra Biosciences, Inc.; share changes are against Q3 2024.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Farallon Capital Management, L.L.C. | 1,000,981 | $13.9M | 0.07% | +1,000,981 | New |
| Vanguard Group Inc | 1,207,765 | $16.8M | 0.00% | −37,643−3.0% | Reduced |
| OrbiMed Advisors LLC | 1,470,086 | $20.4M | 0.42% | +701,448+91.3% | Added |
| BlackRock, Inc. | 1,718,504 | $23.9M | 0.00% | +202,332+13.3% | Added |
| Janus Henderson Group PLC | 1,746,320 | $24.3M | 0.01% | +679,124+63.6% | Added |
| TCG Crossover Management, LLC | 1,989,103 | $27.6M | 2.70% | 00.0% | Unchanged |
| Boxer Capital Management, LLC | 2,027,678 | $28.2M | 2.40% | +2,027,678 | New |
| FMR LLC | 3,107,970 | $43.2M | 0.00% | −264,880−7.9% | Reduced |
| BVF Inc | 3,944,194 | $54.8M | 1.86% | −717,000−15.4% | Reduced |
| Nextech Invest AG | 4,055,861 | $56.4M | 9.15% | 00.0% | Unchanged |
| Alta Partners Management Company, L.P. | 4,080,296 | $56.7M | 89.47% | +4,080,296 | New |
| Canaan Partners XI LLC | 4,179,857 | $58.1M | 75.17% | −230,134−5.2% | Reduced |
| Ra Capital Management, L.P. | 10,637,290 | $147.9M | 1.97% | +220,681+2.1% | Added |
| Boxer Capital, LLC | 0 | $0 | 0.00% | −6,448,359−100.0% | Sold out |
| Frazier Life Sciences Management, L.P. | 0 | $0 | 0.00% | −731,020−100.0% | Sold out |
| Perceptive Advisors LLC | 0 | $0 | 0.00% | −511,226−100.0% | Sold out |
| Jennison Associates LLC | 0 | $0 | 0.00% | −158,187−100.0% | Sold out |
| Tang Capital Management LLC | 0 | $0 | 0.00% | −150,000−100.0% | Sold out |
| Ensign Peak Advisors, Inc | 0 | $0 | 0.00% | −115,616−100.0% | Sold out |
| Woodline Partners LP | 0 | $0 | 0.00% | −55,866−100.0% | Sold out |
| D. E. Shaw & Co., Inc. | 0 | $0 | 0.00% | −32,003−100.0% | Sold out |
| Jane Street Group, LLC | 0 | $0 | 0.00% | −31,003−100.0% | Sold out |
| Cinctive Capital Management LP | 0 | $0 | 0.00% | −22,900−100.0% | Sold out |
| Options Solutions, LLC | 0 | $0 | 0.00% | −21,023−100.0% | Sold out |
| Valence8 US LP | 0 | $0 | 0.00% | −13,188−100.0% | Sold out |
| Balyasny Asset Management LLC | 0 | $0 | 0.00% | −12,988−100.0% | Sold out |
| Mariner, LLC | 0 | $0 | 0.00% | −9,269−100.0% | Sold out |
| Acadian Asset Management LLC | 0 | $0 | 0.00% | −848−100.0% | Sold out |
| nVerses Capital, LLC | 0 | $0 | 0.00% | −400−100.0% | Sold out |
| SRS Capital Advisors, Inc. | 0 | $0 | 0.00% | −7−100.0% | Sold out |
| Capital Performance Advisors LLP | 0 | $0 | 0.00% | −5−100.0% | Sold out |